Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $81.00.
A number of brokerages have issued reports on TECH. Benchmark reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Bio-Techne in a research note on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating on the stock in a research note on Thursday, April 18th. Citigroup cut shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 price objective on the stock. in a research note on Wednesday, May 22nd. Finally, Robert W. Baird raised their price objective on shares of Bio-Techne from $73.00 to $81.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd.
Get Our Latest Report on Bio-Techne
Institutional Trading of Bio-Techne
Bio-Techne Stock Performance
Shares of Bio-Techne stock opened at $82.35 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.08 and a quick ratio of 2.88. The firm has a market cap of $12.98 billion, a P/E ratio of 64.88, a P/E/G ratio of 8.55 and a beta of 1.29. The firm has a 50 day simple moving average of $76.23 and a 200 day simple moving average of $73.16. Bio-Techne has a fifty-two week low of $51.79 and a fifty-two week high of $85.85.
Bio-Techne (NASDAQ:TECH – Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. Bio-Techne had a net margin of 17.59% and a return on equity of 13.60%. The business had revenue of $303.43 million during the quarter, compared to analyst estimates of $292.36 million. During the same quarter last year, the business posted $0.47 earnings per share. Bio-Techne’s revenue for the quarter was up 3.2% compared to the same quarter last year. Sell-side analysts predict that Bio-Techne will post 1.56 earnings per share for the current fiscal year.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
See Also
- Five stocks we like better than Bio-Techne
- Investing in Construction Stocks
- First Solar Stock: The Dawn of a New Rally in Share Prices
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.